Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Oncorena in connection with share issue
Mandate

Vinge advises Oncorena in connection with share issue

July 30, 2025 Capital Markets and Public M&A Life Sciences & Health

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.

The issue proceeds will be used to complete the second part of the clinical study Oncorella-1, which is a phase 1/2 study of safety, tolerability, and anti-tumor efficacy of treatment with ONC175 (Oncorena’s investigational drug product under development) for patients with metastatic clear cell, or papillary renal cell carcinoma, mRCC.

The Vinge team includes Christian Lindhé, Martin Madsen Svanberg and Nathalie Wikman.

Related

Vinge advises as Nimlas expands with dual acquisitions in the electrical sector

 Vinge has advised Nimlas in connection with the acquisitions of Uppsala Elcentral AB and Tjädermo's El AB – two strategic transactions that strengthen the group's position in the Swedish electrical installation market.
February 20, 2026

Vinge advises Zengun in connection with its issuance of bonds in an amount of SEK 750 million and its early redemption of outstanding bonds

 Vinge has advised Zengun Group AB (publ) in connection with its issuance of senior secured bonds in an amount of SEK 750 million (within a framework of SEK 1,500 million) and in parallel with the company's voluntary early redemption of previously issued bonds.
February 20, 2026

Vinge has advised Sluta Gräva in connection with its acquisition of Stavrex

 Vinge has advised Sluta Gräv, a portfolio company of Sobro, in connection with the acquisition of Stavrex. Together, the companies form the Nordic region’s leading supplier of ground screws, with the market’s broadest offering.
February 18, 2026